VRC07-523LS clinical trials
Also written VRC07-523LS.
How each study uses VRC07-523LS is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the VRC07-523LS studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
21 studies that test it; most in 2017 (3)
| Year | Studies |
|---|---|
| 2015 | 2 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 3 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 19
National Institute of Allergy and Infectious Diseases (NIAID) (13) · International AIDS Vaccine Initiative (2) · TaiMed Biologics Inc. (1) · David Ho (1) · Boris Juelg, MD PhD (1) · Gilead Sciences (1) · University of North Carolina, Chapel Hill (1) · Henry M. Jackson Foundation for the Advancement of Military Medicine (1)
Often tested with
Tested in the same studies.
PGDM1400LS (5) · PGT-121 (3) · PGDM1400 (3) · VRC-01LS (2) · VRC-01 (2) · TMB-365 (1) · Ibalizumab (1) · Ad26.Mos4.HIV (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 6
Studies that test VRC07-523LS.
- Jan 2027A Study of VRC07-523LS, PGT121.414.LS, and PGDM1400LS Broadly Neutralizing Monoclonal Antibodies Given Intravenously in Adult Participants Without HIVPhase 2 · National Institute of Allergy and Infectious Diseases (NIAID)
- May 2027HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies StudyPhase 2 · TaiMed Biologics Inc.
- Aug 2027A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) During Analytic Treatment Interruption in Participants Living With HIV Who Initiated ART During Acute/Early HIV-1 InfectionPhase 1 · National Institute of Allergy and Infectious Diseases (NIAID)
- Aug 2027A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1Phase 1 · National Institute of Allergy and Infectious Diseases (NIAID)
- Sep 2027The Tatelo Plus StudyPhase 1/2 · National Institute of Allergy and Infectious Diseases (NIAID)
- Nov 2027Safety and Pharmacokinetics Study of PGT121.414.LS Alone and in Combination With VRC07-523LS in Infants Exposed to HIV-1Phase 1 · National Institute of Allergy and Infectious Diseases (NIAID)
Studies
Open first, then newest update. How each study uses VRC07-523LS is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 21
- A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1RecruitingPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT07390955Written as VRC07-523LS (IV)
- Safety and Pharmacokinetics Study of PGT121.414.LS Alone and in Combination With VRC07-523LS in Infants Exposed to HIV-1RecruitingPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT06517693Written as VRC07-523LS
- A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) During Analytic Treatment Interruption in Participants Living With HIV Who Initiated ART During Acute/Early HIV-1 InfectionNot yet recruitingPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT06987318Written as VRC07-523LS
- Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV RemissionRecruitingPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT02140255Written as VRC07-523LS
- The Tatelo Plus StudyActive, not recruitingPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT06508749Written as VRC07-523LS
- A Study of VRC07-523LS, PGT121.414.LS, and PGDM1400LS Broadly Neutralizing Monoclonal Antibodies Given Intravenously in Adult Participants Without HIVActive, not recruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT06812494Written as VRC07-523LS 400mg
- HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies StudyActive, not recruitingPhase 2TaiMed Biologics Inc.NCT07215468Written as TMB-380
- 10E8.4/iMab Bispecific Antibody and VRC07-523LS Monoclonal Antibody in HIV-infected AdultsActive, not recruitingPhase 1David HoNCT05890963Written as VRC07-523LS
- Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected AdultsCompletedPhase 1/2Boris Juelg, MD PhDNCT04983030Written as VRC07-523LS
- Study of VRC07-523LS, CAP256V2LS, and Vesatolimod, in Early Antiretroviral-treated HIV-1 Clade C-infected WomenCompletedPhase 2Gilead SciencesNCT05281510Written as VRC07523LS
- Evaluating the Safety and Pharmacokinetics of VRC07-523LS in the Sera and Mucosae of Healthy, HIV-Uninfected Adult ParticipantsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT03735849Written as VRC07-523LS
- Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1CompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT03739996Written as VRC07-523LS
- A Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of PGDM1400LS Alone and in Combination With VRC07-523LS and PGT121.414.LS in Healthy, HIV-uninfected Adult ParticipantsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT05184452Written as VRC07-523LS (20mg/kg, IV)
- Phase 1, Open-label, Single Dose Study to Examine Safety, Tolerability, Pharmacokinetics and Virologic Impact of VRC01LS or VRC07-523LS in HIV-infected Viremic AdultsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT02840474Written as VRC-HIVMAB075-00-AB
- Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV RemissionWithdrawnPhase 1Henry M. Jackson Foundation for the Advancement of Military MedicineNCT05769569Written as VRC07-523LS
- Evaluating the Safety and Serum Concentrations of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered in Multiple Doses and Routes to Healthy, HIV-uninfected AdultsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT03387150Written as VRC07-523LS
- Evaluating the Safety and Pharmacokinetics of VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1-Exposed InfantsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT02256631Written as VRC07-523LS
- A Phase 1/2a Study of PGT121, VRC07-523LS and PGDM1400 Monoclonal Antibodies in HIV-uninfected and HIV-infected AdultsCompletedPhase 1/2International AIDS Vaccine InitiativeNCT03721510Written as PGT121 + VRC07-523LS
- Study to Assess Safety and Activity of Combination Therapy of VRC07-523LS and Vorinostat on HIV-infected PersonsCompletedPhase 1University of North Carolina, Chapel HillNCT03803605Written as VRC07-523LS
- VRC 605: Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered Intravenously or Subcutaneously to Healthy AdultsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT03015181Written as VRC-HIVMAB075-00-AB
See all 21 studies that test VRC07-523LS →
Given beside what is tested · 6 — VRC07-523LS is usual care or a partner of the new treatment
- A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV RemissionRecruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT05719441Written as VRC07-523LS
- RV630 - Approach to Control HIV With Immune Enhancement and Vaccination (ACHIEVRecruitingPhase 1Henry M. Jackson Foundation for the Advancement of Military MedicineNCT06484335Written as VRC07-523LS
- Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment InterruptionActive, not recruitingPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT04340596Written as VRC07-523LS
- Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of the Monoclonal Antibody PGT121.414.LS Administered Alone and in Combination With VRC07-523LS Via Intravenous or Subcutaneous Infusions in Healthy, HIV-uninfected Adult ParticipantsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT04212091Written as VRC07-523LS
- Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Combinations of Monoclonal Antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS Administered Via Intravenous Infusion in Healthy, HIV-uninfected Adult ParticipantsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT03928821Written as VRC07-523LS
- Phase I Study to Evaluate a Human Monoclonal Antibody (MAb) 10E8VLS Administered Alone or Concurrently With MAb VRC07-523LS Via Subcutaneous Injection in Healthy AdultsTerminatedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT03565315Written as VRC-HIVMAB075-00-AB (VRC07-523LS)